What question did this study set out to answer?

To review the mechanistic roles of immunoglobulin dysregulation and autoantibodies in recurrent pregnancy loss, alongside emerging biomarkers and targeted immunotherapies.

August 19, 2026Immunologic ResearchOpen Access

Immunoglobulin-mediated immune dysregulation in recurrent pregnancy loss: mechanisms, biomarkers, and therapeutic perspectives

View Full Paper

Ask AI

Bookmark

Authors

KCKamala C PSPallavi Shekar UKUmme Kulsum

Discussion

Member takes

Overview

Comprehensive review uncovers immunoglobulin-mediated immune dysregulation mechanisms in recurrent pregnancy loss, highlighting opportunities for biomarker profiling and targeted immunotherapy.

Key Points

To review the mechanistic roles of immunoglobulin dysregulation and autoantibodies in recurrent pregnancy loss, alongside emerging biomarkers and targeted immunotherapies.
Synthesized molecular and clinical evidence regarding immunoglobulin profiles, IgG subclass alterations, and pathogenic autoantibodies in maternal-fetal tolerance.
Assessed downstream pathological mechanisms including impaired trophoblast invasion, thrombosis, and endothelial dysfunction, while evaluating clinical efficacy of intravenous immunoglobulin.
Pathogenic autoantibodies, including antiphospholipid and antinuclear antibodies, drive adverse pregnancy outcomes by impairing trophoblast invasion, inducing endothelial dysfunction, and promoting thrombosis.
Regulatory B cells and balanced immunoglobulin networks serve essential functions in maintaining maternal-fetal tolerance and preventing cytokine imbalance.
Intravenous immunoglobulin therapy demonstrates clinical utility in select stratified patient subsets, though variable response rates emphasize the necessity of precision biomarker profiling.

Cite This Study

C et al. (2026) studied this question.

synapsesocial.com/papers/6a858aaf03308d306e2d7eb8 https://doi.org/10.1007/s12026-026-09820-z

View Full Paper

Ask AI

Bookmark

August 19, 2026Immunologic ResearchOpen Access

Immunoglobulin-mediated immune dysregulation in recurrent pregnancy loss: mechanisms, biomarkers, and therapeutic perspectives

View Full Paper

Ask AI

Bookmark

Authors

KCKamala C PSPallavi Shekar UKUmme Kulsum

Discussion

Member takes

Overview

Comprehensive review uncovers immunoglobulin-mediated immune dysregulation mechanisms in recurrent pregnancy loss, highlighting opportunities for biomarker profiling and targeted immunotherapy.

Key Points

To review the mechanistic roles of immunoglobulin dysregulation and autoantibodies in recurrent pregnancy loss, alongside emerging biomarkers and targeted immunotherapies.
Synthesized molecular and clinical evidence regarding immunoglobulin profiles, IgG subclass alterations, and pathogenic autoantibodies in maternal-fetal tolerance.
Assessed downstream pathological mechanisms including impaired trophoblast invasion, thrombosis, and endothelial dysfunction, while evaluating clinical efficacy of intravenous immunoglobulin.
Pathogenic autoantibodies, including antiphospholipid and antinuclear antibodies, drive adverse pregnancy outcomes by impairing trophoblast invasion, inducing endothelial dysfunction, and promoting thrombosis.
Regulatory B cells and balanced immunoglobulin networks serve essential functions in maintaining maternal-fetal tolerance and preventing cytokine imbalance.
Intravenous immunoglobulin therapy demonstrates clinical utility in select stratified patient subsets, though variable response rates emphasize the necessity of precision biomarker profiling.

Cite This Study

C et al. (2026) studied this question.

synapsesocial.com/papers/6a858aaf03308d306e2d7eb8 https://doi.org/10.1007/s12026-026-09820-z

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark